Alpha 2.0
Login Register
» Authors » Hironori Yoshida

Hironori Yoshida

Explore the profile of Hironori Yoshida including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 491
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Science
Top 10 Co-Authors
Hiroaki Ozasa
Toyohiro Hirai
Yuichi Sakamori
Young Hak Kim
Takashi Nomizo
Takahiro Tsuji
Hitomi Ajimizu
Tomoko Funazo
Hiroki Nagai
Yuto Yasuda
Published In
Mol Clin Oncol
Sci Rep
J Thorac Oncol
Anticancer Res
In Vivo
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study
Shima Y, Yoshida H, Suminaga K, Yoshida H, Hashimoto K, Ogimoto T, et al.
BMC Cancer . 2025 Mar; 25(1):388. PMID: 40038680
Background: Pemetrexed is a key treatment for non-small-cell lung cancer (NSCLC), and its usage is increasing. However, owing to treatment-related fatality in a patient with severe renal impairment observed during...
2.
The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
Suminaga K, Nomizo T, Yoshida H, Ozasa H
J Cancer Res Clin Oncol . 2025 Feb; 151(2):61. PMID: 39903279
Purpose: This study aims to clarify the relationship between rs2282055, a single-nucleotide polymorphism (SNP) in programmed death-ligand 1 (PD-L1), and TPS. Polcaro et al. (2024) showed that rs822336, a SNP...
3.
Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study
Yokoi M, Yonezawa A, Hira D, Handa T, Tanizawa K, Nakagawa S, et al.
J Pharm Health Care Sci . 2024 Aug; 10(1):52. PMID: 39192314
Background: Interstitial lung disease (ILD) is one of the most common fatal immune-related adverse events (irAEs). ILD development adversely affects the continuation of anticancer drug therapy, including immune checkpoint inhibitor...
4.
Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients
Hosoya K, Ozasa H, Tanji M, Yoshida H, Ajimizu H, Tsuji T, et al.
BMC Cancer . 2024 Aug; 24(1):1030. PMID: 39169327
Background: Brain metastasis (BrM) is prevalent among patients with NSCLC, and surgical resection of BrM constitutes a promising treatment strategy for local management and histopathological diagnosis, although it is offered...
5.
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, et al.
J Clin Invest . 2024 Apr; 134(7). PMID: 38557498
BACKGROUNDPrecise stratification of patients with non-small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy.METHODSWe measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4...
6.
Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report
Natori D, Ozasa H, Shima Y, Mizumoto C, Suminaga K, Nomizo T, et al.
Mol Clin Oncol . 2024 Mar; 20(4):33. PMID: 38476337
The combined occurrence of lung cancer and B-cell lymphoma, such as mucosa-associated lymphoid tissue (MALT) lymphoma, is rare. The efficacy and safety of immune checkpoint inhibitors (ICIs) remain unknown in...
7.
Connective tissue growth factor enhances TGF-β1-induced osteogenic differentiation via activation of p38 MAPK in mesenchymal stem cells
Yoshida H, Yokota S, Satoh K, Ishisaki A, Chosa N
J Oral Biosci . 2024 Jan; 66(1):68-75. PMID: 38266705
Objectives: Cellular differentiation is based on the effects of various growth factors. Transforming growth factor (TGF)-β1 plays a pivotal role in inducing osteogenic differentiation of mesenchymal stem cells (MSCs). In...
8.
Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer
Ogimoto T, Ozasa H, Tsuji T, Funazo T, Yamazoe M, Hashimoto K, et al.
Mol Cancer Ther . 2023 Dec; 23(4):564-576. PMID: 38052760
EGFR-tyrosine kinase inhibitors (TKI) are the first-line therapies for EGFR mutation-positive lung cancer. EGFR-TKIs have favorable therapeutic effects. However, a large proportion of patients with EGFR mutation-positive lung cancer subsequently...
9.
polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer
Ogimoto T, Ozasa H, Yoshida H, Nomizo T, Funazo T, Yoshida H, et al.
Oncol Lett . 2023 Aug; 26(2):364. PMID: 37545625
Immune checkpoint inhibitors (ICIs), such as nivolumab, play an essential role in non-small-cell lung cancer (NSCLC) treatment. Programmed death ligand-1 has been used as a predictive biomarker for the efficacy...
10.
Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer
Yuasa I, Hamaji M, Ozasa H, Sakamori Y, Yoshida H, Yutaka Y, et al.
Gen Thorac Cardiovasc Surg . 2023 Feb; 71(9):534-541. PMID: 36811789
Objectives: Immune checkpoint inhibitors (ICIs) are effective treatment options for patients with advanced non-small cell lung cancer (NSCLC); however, there is a dearth of data on outcomes of patients receiving...